Your browser doesn't support javascript.
loading
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang, Eun Young; Cheasley, Dane; LePage, Cecile; Wakefield, Matthew J; da Cunha Torres, Michelle; Rowley, Simone; Salazar, Carolina; Xing, Zhongyue; Allan, Prue; Bowtell, David D L; Mes-Masson, Anne-Marie; Provencher, Diane M; Rahimi, Kurosh; Kelemen, Linda E; Fasching, Peter A; Doherty, Jennifer A; Goodman, Marc T; Goode, Ellen L; Deen, Suha; Pharoah, Paul D P; Brenton, James D; Sieh, Weiva; Mateoiu, Constantina; Sundfeldt, Karin; Cook, Linda S; Le, Nhu D; Anglesio, Michael S; Gilks, C Blake; Huntsman, David G; Kennedy, Catherine J; Traficante, Nadia; DeFazio, Anna; Kaufmann, Scott; Churchman, Michael; Gourley, Charlie; Stephens, Andrew N; Meagher, Nicola S; Ramus, Susan J; Antill, Yoland C; Campbell, Ian; Scott, Clare L; Köbel, Martin; Gorringe, Kylie L.
Afiliação
  • Kang EY; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
  • Cheasley D; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • LePage C; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Wakefield MJ; Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.
  • da Cunha Torres M; Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.
  • Rowley S; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Salazar C; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Xing Z; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Allan P; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Bowtell DDL; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Mes-Masson AM; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Provencher DM; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Rahimi K; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Kelemen LE; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Fasching PA; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Doherty JA; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Goodman MT; Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.
  • Goode EL; Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.
  • Deen S; Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.
  • Pharoah PDP; Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.
  • Brenton JD; Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.
  • Sieh W; Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.
  • Mateoiu C; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
  • Sundfeldt K; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Cook LS; Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
  • Le ND; Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Anglesio MS; Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
  • Gilks CB; Department of Histopathology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Huntsman DG; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Kennedy CJ; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Traficante N; Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • DeFazio A; Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
  • Kaufmann S; Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.
  • Churchman M; University of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, NM, USA.
  • Gourley C; Cancer Control Research, BC Cancer Research Centre, Vancouver, BC, Canada.
  • Stephens AN; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
  • Meagher NS; Cancer Control Research, BC Cancer Research Centre, Vancouver, BC, Canada.
  • Ramus SJ; British Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver General Hospital, Vancouver, BC, Canada.
  • Antill YC; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Campbell I; Cancer Control Research, BC Cancer Research Centre, Vancouver, BC, Canada.
  • Scott CL; British Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver General Hospital, Vancouver, BC, Canada.
  • Köbel M; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Gorringe KL; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia.
Mod Pathol ; 34(1): 194-206, 2021 01.
Article em En | MEDLINE | ID: mdl-32724153
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Análise Mutacional de DNA / Imuno-Histoquímica / Biomarcadores Tumorais / Proteína Supressora de Tumor p53 / Neoplasias Císticas, Mucinosas e Serosas / Mutação Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Middle aged País/Região como assunto: America do norte / Europa / Oceania Idioma: En Revista: Mod Pathol Assunto da revista: PATOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Análise Mutacional de DNA / Imuno-Histoquímica / Biomarcadores Tumorais / Proteína Supressora de Tumor p53 / Neoplasias Císticas, Mucinosas e Serosas / Mutação Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Middle aged País/Região como assunto: America do norte / Europa / Oceania Idioma: En Revista: Mod Pathol Assunto da revista: PATOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá